natgillin/translations-raw huggingface dataset:
Carcinogenicity studies have not been conducted with avibactam. 
Študij kancerogenosti z avibaktamom niso izvedli.
After reconstitution 
Po rekonstituciji:
• diarrhoea that keeps getting worse or does not go away, or stools that contains blood or mucus this may happen during or after treatment is stopped with Zavicefta. 
• Drisko, ki se slabša ali ne mine, ali blato, ki vsebuje kri ali sluz - driska se lahko pojavi med zdravljenjem z zdravilom Zavicefta ali po koncu zdravljenja z njim.
• Ceftazidime belongs to the group of antibiotics called “cephalosporins”. 
• Ceftazidim spada v skupino antibiotikov, imenovanih "cefalosporini".
Ceftazidime and avibactam are eliminated via the kidneys, therefore, the dose should be reduced according to the degree of renal impairment (see section 4.2). 
Ceftazidim in avibaktam se izločita skozi ledvice, zato je treba odmerek zmanjšati glede na stopnjo okvare ledvic (glejte poglavje 4.2).
The effects of ceftazidime/avibactam on fertility in humans have not been studied. 
Vplivi ceftazidima/avibaktama na plodnost pri človeku niso raziskani.
The maximum daily dose of this product is equivalent to 22.2% of the WHO recommended maximum daily intake for sodium. 
Največji dnevni odmerek tega zdravila ustreza 22,2 % največjega dnevnega vnosa natrija, ki ga priporoča WHO.
Summary of the safety profile 
Povzetek varnostnih značilnosti
Complicated intra-abdominal infections 
Zapletene intraabdominalne okužbe
Patients experiencing anaemia during or after treatment with Zavicefta should be investigated for this possibility. 
Pri bolnikih, ki se jim med zdravljenjem z zdravilom Zavicefta ali po njem pojavi anemija, je treba raziskati to možnost.
• Staphylococcus aureus (methicillin-susceptible and methicillin-reistant) 
• Staphylococcus aureus (tako občutljiv kot odporen na meticilin)
While DAGT seroconversion in patients receiving Zavicefta was very common in clinical studies (the estimated range of seroconversion across Phase 3 studies was 3.2% to 20.8% in patients with a negative Coombs test at baseline and at least one followup test), there was no evidence of haemolysis in patients who developed a positive DAGT on treatment. 
V kliničnih študijah je bila serokonverzija DAGT pri bolnikih, ki so prejemali zdravilo Zavicefta, zelo pogosta (ocenjeni razpon serokonverzij v študijah 3. faze je bil od 3,2 do 20,8 % pri bolnikih, ki so imeli izhodiščno negativen Coombsov test in vsaj še enega med spremljanjem), a pri bolnikih, ki se jim je med zdravljenjem pojavil pozitiven DAGT, ni bilo dokazov o hemolizi.
How much to use The recommended dose is one vial (2 g of ceftazidime and 0.5 g of avibactam), every 8 hours. 
Koliko zdravila uporabiti Priporočeni odmerek je ena viala (2 g ceftazidima in 0,5 g avibaktama) na 8 ur.
Following administration of avibactam throughout pregnancy and lactation in the rat, there was no effect on pup survival, growth or development, however there was an increase in incidence of dilation of the renal pelvis and ureters in less than 10% of the rat pups at maternal exposures greater than or equal to approximately 1.5 times human therapeutic exposures. 
Uporaba avibaktama med celotno brejostjo in obdobjem dojenja pri podganah ni vplivala na preživetje mladičev, njihovo rast ali razvoj, ugotovili pa so večjo pojavnost razširjenih ledvičnih mehov in sečevodov, a pri manj kot 10 % mladičev podgan, pri katerih je bila izpostavljenost ≥ 1,5-kratniku terapevtske izpostavljenosti pri človeku.
The following side effects may happen with this medicine: 
Med uporabo tega zdravila se lahko pojavijo naslednji neželeni učinki:
• you have ever had any allergic reaction (even if only a skin rash) to other antibiotics belonging to the penicillin or carbapenem groups 
• če ste kdaj imeli kakršno koli alergijsko reakcijo (tudi če je bil to le izpuščaj na koži) na druge antibiotike, ki spadajo v skupino penicilinov ali karbapenemov.
Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis. 
Koncentracijo ceftazidima v serumu je mogoče zmanjšati s hemodializo ali peritonealno dializo.
What you need to know before you use Zavicefta 
Kaj morate vedeti, preden boste uporabili zdravilo Zavicefta
Lab tests 
Laboratorijske preiskave
Following a single intravenous administration of 500 mg avibactam as a 30-minute IV infusion, the elderly had a slower terminal half-life of avibactam, which may be attributed to age related decrease in renal clearance. 
Po enkratnem intravensko uporabljenem odmerku 500 mg avibaktama v 30-minutni intravenski infuziji so imeli starejši bolniki daljši terminalni razpolovni čas avibaktama, kar je morda mogoče pripisati starostnemu zmanjšanju ledvičnega očistka.
People with kidney problems 
Osebe, ki imajo težave z ledvicami
Minimum Inhibitory Concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for ceftazidime/avibactam are as follows: Organisms 
Mejni vrednosti minimalne inhibitorne koncentracije (MIC - Minimum Inhibitory Concentration), ki ju je za ceftazidim/avibaktam postavil Evropski odbor za testiranje protimikrobne občutljivosti (EUCAST - European Committee on Antimicrobial Susceptibility Testing), sta:
5-14 days 
5-14 dni
Gram-negative micro-organisms 
Gramnegativni mikroorganizmi
Non-susceptible organisms 
Neobčutljivi organizmi
Introduce the syringe needle through the vial closure and inject 10 mL of sterile water for injections. 
Vstavite iglo brizge skozi zaporko viale in injicirajte 10 ml sterilne vode za injekcije.
• Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) 
• bolnišnične pljučnice (HAP - hospital-acquired pneumonia), vključno s pljučnico zaradi uporabe respiratorja (VAP - ventilator associated pneumonia).
Vials of ceftazidime/avibactam powder should be reconstituted with 10 mL of sterile water for injections, followed by shaking until the content dissolves. 
Viale s praškom ceftazidima/avibaktama je treba pripraviti z 10 ml sterilne vode za injekcije in jih nato stresati, dokler se vsebina ne raztopi.
Do not use Zavicefta if any of the above apply to you. 
Ne uporabljajte zdravila Zavicefta, če kaj od naštetega velja za vas.
Do not insert a gas relief needle until the product has dissolved. 
Ne vstavite odzračevalne igle, dokler se zdravilo ne raztopi.
The concentration time profiles are similar for ELF and plasma. 
Časovni potek koncentracij v epitelijski tekočini in plazmi je podoben.
Avibactam and ceftazidime do not inhibit the major renal or hepatic transporters in the clinically relevant exposure range, therefore the interaction potential via these mechanisms is considered to be low. 
Avibaktam in ceftazidim v klinično pomembnem razponu ne zavirata glavnih ledvičnih in jetrnih prenašalcev, zato velja, da je možnost za medsebojno delovanje preko teh mehanizmov majhna.
This should be considered when administering Zavicefta to patients who are on a controlled sodium diet. 
To je treba upoštevati v primeru uporabe zdravila Zavicefta pri bolnikih, ki so na dieti z omejeno količino natrija.
Ask your pharmacist how to throw away medicines you no longer require. 
O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
Direct antiglobulin test (DAGT or Coombs test) seroconversion and potential risk of haemolytic anaemia 
Serokonverzija direktnega antiglobulinskega testa (DAGT - direct antiglobulin test ali Coombsov test) in možno tveganje za hemolitično anemijo
Infections due to aerobic Gram-negative organisms in patients with limited treatment options 
Okužbe z aerobnimi gramnegativnimi bakterijami pri bolnikih z omejenimi možnostmi zdravljenja
Interference with laboratory tests 
Moteči vplivi na laboratorijske preiskave
Talk to your doctor before using Zavicefta if you are taking any of the following medicines: 
Pred uporabo zdravila Zavicefta se posvetujte z zdravnikom, če jemljete katero od naslednjih zdravil:
For instructions on reconstitution and dilution of the medicinal product before administration see section 6.6. 
Za navodila o pripravi in redčenju zdravila pred uporabo glejte poglavje 6.6.
A dose of 1000 mg/250 mg or 750 mg/187.5 mg is achieved with 6.0 mL or 4.5 mL aliquots, respectively. 
Odmerek 1000 mg/250 mg ali 750 mg/187,5 mg je mogoče dobiti z alikvotoma 6,0 ml ali 4,5 ml.
The antimicrobial activity of ceftazidime against specific pathogens has been shown to best correlate with the percent time of free-drug concentration above the ceftazidime/avibactam minimum inhibitory concentration over the dose interval (%fT >MIC of ceftazidime/avibactam). 
Ugotovljeno je, da protimikrobno delovanje ceftazidima proti specifičnim patogenom najbolje korelira z odstotkom časa, ko je koncentracija prostega zdravila v odmernem intervalu nad minimalno inhibicijsko koncentracijo ceftazidima/avibaktama (% fT > MIC ceftazidima/avibaktama).
Bacterial resistance mechanisms that could potentially affect ceftazidime/avibactam include mutant or acquired PBPs, decreased outer membrane permeability to either compound, active efflux of either compound, and β-lactamase enzymes refractory to inhibition by avibactam and able to hydrolyse ceftazidime. 
Med mehanizme bakterijske odpornosti, ki bi potencialno lahko vplivali na ceftazidim/avibaktam, spadajo mutirani ali pridobljeni PBP, zmanjšanje permeabilnosti zunanje membrane za eno ali drugo učinkovino, aktivno izločanje ene ali druge učinkovine in betalaktamaze, ki so odporne proti zavrtju z avibaktamom in lahko hidrolizirajo ceftazidim.
Clinical data have demonstrated that there is no interaction between ceftazidime and avibactam, and between ceftazidime/avibactam and metronidazole. 
Klinični podatki so pokazali, da med ceftazidimom in avibaktamom ter med kombinacijo ceftazidim/avibaktam in metronidazol ni medsebojnih delovanj.
The terminal half-life (t½) of both ceftazidime and avibactam is about 2 h after intravenous administration. 
Terminalni razpolovni čas (t1/2) ceftazidima in avibaktama je po intravenski uporabi približno 2 uri.
Hospital-acquired pneumonia, including ventilator-associated pneumonia In a single study in patients with nosocomial pneumonia 280/808 (34.7%) had VAP and 40/808 (5.0%) were bacteraemic at baseline. 
Bolnišnična pljučnica, vključno s pljučnico zaradi uporabe respiratorja V študiji pri bolnikih z bolnišnično pljučnico je 280 od 808 bolnikov (34,7 %) imelo VAP in 40 od 808 bolnikov (5,0 %) bakteriemijo na začetku študije.
Infusion time 
Čas infundiranja
Tell the person taking the sample that you have been given Zavicefta. 
Povejte osebi, ki ji oddate vzorec urina, da prejemate zdravilo Zavicefta.
powder for concentrate for solution for infusion 10 vials 
prašek za koncentrat za raztopino za infundiranje 10 vial
The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied. 
Farmakokinetika avibaktama pri bolnikih s katero koli stopnjo okvare jeter ni raziskana.
The colour of Zavicefta infusion solution is pale yellow and free of particles. 
Raztopina za infundiranje zdravila Zavicefta je bledo rumena in brez delcev.
Insert a gas relief needle through the vial closure to relieve the internal pressure. 
Skozi zaporko viale vstavite odzračevalno iglo, da se bo notranji tlak izravnal.
What Zavicefta is and what it is used for 
Kaj je zdravilo Zavicefta in za kaj ga uporabljamo
Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of β-lactam antibacterial agent (e.g. penicillins, monobactams or carbapenems). 
Huda preobčutljivost (npr. anafilaktična reakcija, huda kožna reakcija) za katero koli drugo vrsto betalaktamskih antibiotikov (npr. na peniciline, monobaktame ali karbapeneme).
Discontinuation of therapy with Zavicefta and the administration of specific treatment for Clostridium difficile should be considered. 
V poštev pride prenehanje zdravljenja z zdravilom Zavicefta in uporaba specifičnih zdravil proti Clostridium difficile.
However, if you have side effects or think you have been given too much Zavicefta, tell your doctor or nurse straight away. 
Toda če imate neželene učinke, ali če menite, da ste dobili preveč zdravila Zavicefta, to nemudoma povejte zdravniku ali medicinski sestri.
Both ceftazidime and avibactam penetrate into human bronchial epithelial lining fluid (ELF) to the same extent with concentrations around 30% of those in plasma. 
Ceftazidim in avibaktam pri človeku prodirata v bronhialno epitelijsko tekočino v enaki meri in v njej dosežeta koncentracijo, ki znaša približno 30 % koncentracije v plazmi.
The use of ceftazidime/avibactam to treat patients with infections due to Gram-negative aerobic pathogens who have limited treatment options is based on experience with ceftazidime alone and on analyses of the pharmacokinetic-pharmacodynamic relationship for ceftazidime/avibactam (see section 
Uporaba ceftazidima/avibaktama za okužbe z gramnegativnimi aerobnimi patogeni pri bolnikih, pri katerih so možnosti zdravljenja omejene, temelji le na izkušnjah s samim ceftazidimom in na analizah farmakokinetičnega/farmakodinamičnega razmerja za kombinacijo ceftazidim/avibaktam (glejte poglavje 5.1).
In two studies in patients with cUTI, 381/1091 (34.9%) patients were enrolled with cUTI without pyelonephritis while 710 (65.1%) were enrolled with acute pyelonephritis (mMITT population). 
V dve študiji bolnikov z zapletenimi okužbami sečil je bilo vključenih 381/1091 (34,9 %) bolnikov z zapletenimi okužbami sečil brez pielonefritisa in 710 (65,1 %) z akutnim pielonefritisom (populacija mMITT - microbiological Modified Intention to Treat).
Zavicefta is an antibiotic medicine that contains two active substances ceftazidime and avibactam. 
Zdravilo Zavicefta je antibiotično zdravilo, ki vsebuje dve učinkovini: ceftazidim in avibaktam.
Complicated IAI 
Zapletene IAI
• Complicated urinary tract infection (cUTI), including pyelonephritis 
• zapletenih okužb sečil (cUTI - complicated urinary tract infection), vključno s pielonefritisom,
This is because you may get an abnormal result with a test called “DAGT” or “Coombs”. 
Lahko se namreč zgodi, da boste imeli zaradi tega zdravila nenormalen izvid preiskave, imenovane "DAGT" oz. "Coombsov test".
The reconstituted solution must be further diluted to produce Zavicefta solution for infusion. 
Pripravljeno raztopino je treba dodatno razredčiti, da nastane raztopina zdravila Zavicefta za infundiranje.
Name and address of the manufacturer(s) responsible for batch release 
Ime in naslov izdelovalca, odgovornega za sproščanje serij
• change in the number of some types of blood cells (called “eosinophils” and “thrombocytes”) 
• sprememba števila nekaterih vrst krvnih celic (imenovanih "eozinofilci" in "trombociti")
Avibactam is a non β-lactam, βlactamase inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis. 
Avibaktam je nebetalaktamski zaviralec betalaktamaze; deluje s tvorbo kovalentnega addukta z encimom, ki je stabilen pri hidrolizi.
Elderly No dosage adjustment is required in elderly patients (see section 5.2). 
Starejši Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
Important: Please refer to the Summary of Product Characteristics before prescribing. 
Pomembno: Preden predpišete to zdravilo, glejte povzetek glavnih značilnosti zdravila.
Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death. 
Ceftazidim z vezavo na penicilin vezavne proteine (PBP - penicillin binding proteins) zavre sintezo peptidoglikana bakterijske celične stene in tako povzroči lizo in odmrtje bakterijske celice.
Among a subgroup with baseline CrCL 30 to 50 mL/min death occurred in 16.7% (9/54) of patients who received Zavicefta and metronidazole and 6.8% (4/59) of patients who received meropenem. 
V podskupini z izhodiščnim očistkom kreatinina (CrCL) 30 do 50 ml/min se je smrt pojavila pri 16,7 % (9/54) bolnikih, ki so prejeli zdravilo Zavicefta in metronidazol in pri 6,8 % (4/59) bolnikih, ki so prejeli meropenem.
Powder for concentrate for solution for infusion (powder for concentrate). 
prašek za koncentrat za raztopino za infundiranje (prašek za koncentrat)
• abnormal result with a test called “DAGT” or “Coombs”. 
• nenormalen izvid preiskave, imenovane "DAGT" oz. "Coombsov test".
Avibactam penetration of the blood brain barrier has not been studied clinically; however, in rabbits with inflamed meninges, CSF exposures of ceftazidime and avibactam were 43% and 38% of plasma AUC, respectively. 
Prodiranje avibaktama skozi krvno-možgansko pregrado ni klinično raziskano, a je bila pri kuncih z vnetjem mening izpostavljenost ceftazidimu v cerebrospinalni tekočini 43 % AUC v plazmi, avibaktamu pa 38 % AUC v plazmi.
• an infection of the lungs called “pneumonia” 
• okužbe pljuč, ki jo imenujemo "pljučnica",
Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4 and 5.1). 
Zdravilo Zavicefta je indicirano tudi za zdravljenje okužb z aerobnimi gramnegativnimi bakterijami pri odraslih bolnikih, pri katerih so možnosti zdravljenja omejene (glejte poglavja 4.2, 4.4 in 5.1).
• The other ingredient is sodium carbonate (anhydrous). 
• Druga sestavina zdravila je natrijev karbonat (brezvodni).
Carcinogenicity studies have not been conducted with ceftazidime. 
Študij kancerogenosti s ceftazidimom niso izvedli.
These include thrush (fungal infections of the mouth or genital area). 
To vključuje kandidozo (glivično okužbo v ustih ali predelu spolovil).
Mild to moderate hepatic impairment had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired. 
Blaga do zmerna okvara jeter ni vplivala na farmakokinetiko ceftazidima pri osebah, ki so 5 dni prejemale 2 g ceftazidima na 8 ur intravensko in niso imele okvarjenega delovanja ledvic.
Marketing Authorisation Holder Pfizer Ireland Pharmaceuticals Operations Support Group Ringaskiddy, County Cork Ireland 
Imetnik dovoljenja za promet z zdravilom Pfizer Ireland Pharmaceuticals Operations Support Group Ringaskiddy, County Cork Irska
The contents of Zavicefta vial should be reconstituted with 10 mL of sterile water for injections. 
Vsebino viale zdravila Zavicefta je treba pripraviti z 10 ml sterilne vode za injekcije.
Very common (≥1/10) 
Zelo pogosti ≥ 1/10)
Dry powder 
Suhi prašek:
Justification for not including Braille accepted 
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
Undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines following administration of Zavicefta (see section 4.8). 
Po uporabi zdravila Zavicefta se lahko pojavijo neželeni učinki (npr. omotica), ki lahko vplivajo na sposobnost vožnje in upravljanja strojev (glejte poglavje 4.8).
Hypersensitivity reactions 
Preobčutljivostne reakcije
If you miss a dose of Zavicefta If you think you have missed a dose, tell your doctor or nurse straight away. 
Če ste izpustili odmerek zdravila Zavicefta Če menite, da ste izpustili odmerek, morate to takoj povedati zdravniku ali medicinski sestri.
• a medicine for gout called probenecid 
• zdravilo proti protinu, imenovano probenecid.
Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to ceftazidime/avibactam in vitro. 
Učinkovitost je bila v kliničnih študijah dokazana proti naslednjim patogenom, ki so bili in vitro občutljivi za ceftazidim/avibaktam.
If you have any further questions on the use of this medicine, ask your doctor or nurse. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali medicinsko sestro.
Ceftazidime may interfere with copper reduction methods (Benedict's, Fehling's, Clinitest) for detection of glycosuria leading to false positive results. 
Ceftazidim lahko vpliva na teste za odkrivanje glikozurije, ki temeljijo na metodah z redukcijo bakra (Benedictova reakcija, Fehlingova reakcija, Clinitest), kar lahko vodi do lažno pozitivnih rezultatov.
For avibactam the PK-PD index is the percent time of the free drug concentration above a threshold concentration over the dose interval (% fT >CT). 
Za avibaktam je farmakokinetično-farmakodinamični indeks odstotek časa, ko je koncentracija prostega zdravila v odmernem intervalu nad pražno koncentracijo (% fT > CT).
The inhibitory spectrum of avibactam includes many of the enzymes that inactivate ceftazidime, including Ambler class A β-lactamases and class C β-lactamases. 
Inhibicijski spekter avibaktama vključuje več encimov, ki inaktivirajo ceftazidim; med takšnimi so betalaktamaze razreda A in betalaktamaze razreda C po Amblerju.
Unchanged avibactam was the major drug-related component in human plasma and urine following dosing with [ 
C]-avibaktama je bil glavna z zdravilom povezana snov v človeški plazmi in urinu nespremenjeni avibaktam.
The human protein binding of both ceftazidime and avibactam is approximately 10% and 8%, respectively. 
Vezava ceftazidima in avibaktama na človeške proteine je približno 10 % za ceftazidim in približno 8 % za avibaktam.
If you have any further questions, ask your doctor or nurse. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali medicinsko sestro.
There is a small possibility that you may get a different infection caused by another bacteria during or after treatment with Zavicefta. 
Obstaja majhna verjetnost, da se vam med zdravljenjem z zdravilom Zavicefta ali po zdravljenju z njim pojavi drugačna okužba, ki jo povzročajo druge bakterije.
The reconstituted solution is pale yellow solution and free of particles. 
Pripravljena raztopina je bledo rumena in brez delcev.
If any of the above apply to you (or you are not sure), talk to your doctor or nurse before using Zavicefta. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se pred uporabo zdravila Zavicefta posvetujte z zdravnikom ali medicinsko sestro.
Chloramphenicol is antagonistic in vitro with ceftazidime and other cephalosporins. 
Kloramfenikol je in vitro antagonist ceftazidima in drugih cefalosporinov.
Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many class D enzymes. 
Avibaktam ne zavira encimov razreda B (metalo-betalaktamaz) in ne more zavreti veliko encimov razreda D.
A white to yellow powder. 
Bel do rumen prašek.
• you are allergic to other cephalosporin antibiotics 
• če ste alergični na druge cefalosporinske antibiotike.
20 mL glass vial (Type 1) closed with a rubber (halobutyl) stopper and aluminium seal with flip-off cap. 
20-ml steklena viala (iz stekla tipa 1), zaprta z gumijastim (halobutilnim) zamaškom, aluminijsko zaporo in snemljivim pokrovčkom.
Ceftazidime crosses the placenta readily, and is excreted in the breast milk. 
Ceftazidim zlahka prehaja placento in se izloča v materino mleko.
This is because Zavicefta is removed from your body by the kidneys. 
Zdravilo Zavicefta se namreč izloča iz telesa skozi ledvice.
In pregnant rabbits administered avibactam at 300 and 1000 mg/kg/day, there was a dose-related lower mean foetal weight and delayed ossification, potentially related to maternal toxicity. 
Pri brejih samicah kuncev, ki so dobivale avibaktam v odmerkih 300 in 1000 mg/kg/dan, so ugotavljali z odmerkom povezano zmanjšanje povprečne telesne mase plodov in zapoznelo osifikacijo; morda je bilo to povezano s toksičnostjo za samice-matere.
Animal studies with avibactam have shown reproductive toxicity without evidence of teratogenic effects (see section 5.3). 
Študije avibaktama na živalih so pokazale vpliv na sposobnost razmnoževanja brez znakov teratogenosti (glejte poglavje 5.3).
Withdraw the needle and shake the vial to give a clear solution. 
Izvlecite iglo in pretresite vialo, da nastane bistra raztopina.
Other medicines and Zavicefta Tell your doctor or nurse if you are using, have recently used or might use any other medicines. 
Obvestite zdravnika ali medicinsko sestro, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.